Gene regulatory network inference from CRISPR perturbations in primary CD4+ T cells elucidates the genomic basis of immune disease
The effects of genetic variation on complex traits act mainly through changes in gene regulation. Although many genetic variants have been linked to target genes in cis, the trans-regulatory cascade mediating their effects remains largely uncharacterized. Mapping trans-regulators based on natural genetic variation has been challenging due to small effects, but experimental perturbations offer a complementary approach. Using CRISPR, we knocked out 84 genes in primary CD4<sup>+</sup> T cells, targeting inborn error of immunity (IEI) disease transcription factors (TFs) and TFs without immune disease association. We developed a novel gene network inference method called linear latent causal Bayes (LLCB) to estimate the network from perturbation data and observed 211 regulatory connections between genes. We characterized programs affected by the TFs, which we associated with immune genome-wide association study (GWAS) genes, finding that JAK-STAT family members are regulated by KMT2A, an epigenetic regulator. These analyses reveal the trans-regulatory cascades linking GWAS genes to signaling pathways.
Authors
- Jacob W. Freimer (ORCID: https://orcid.org/0000-0001-9239-2272)
- Jonathan K. Pritchard (ORCID: https://orcid.org/0000-0002-8828-5236)
- Joshua S. Weinstock (ORCID: https://orcid.org/0000-0001-7013-1899)
- Alexis Battle (ORCID: https://orcid.org/0000-0002-5287-627X)
- Alexander Marson (ORCID: https://orcid.org/0000-0002-2734-5776)
- Maya M. Arce (ORCID: https://orcid.org/0000-0003-4234-9908)
- Mineto Ota (ORCID: https://orcid.org/0000-0003-4552-8573)
Institutions
- Gladstone Institutes (US)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Johns Hopkins Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Cell Genomics
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1016/j.xgen.2024.100671
- Citations
- 12
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- National Science Foundation
- Cancer Research Institute
- Simons Foundation
- Innovative Genomics Institute
- Parker Institute for Cancer Immunotherapy
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Chugai Pharmaceutical
- National Human Genome Research Institute
- National Institute of General Medical Sciences